#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16960	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2001	840.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1663	1663	T	945	T	860	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16960	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2001	840.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1397	1397	C	971	C,T	891,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31230	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3614	862.2	0	.	n	.	0	T695C	SNP	695	695	T	1030	1030	C	940	C	877	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31230	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3614	862.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2306	2306	C	956	C	881	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31230	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3614	862.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2380	2380	A	976	A,C	904,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31230	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3614	862.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	2932	2932	C	955	C	897	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	539	2124	folP	852	852	99.88	folP.l15.c4.ctg.1	1613	131.1	0	.	p	.	0	S68P	NONSYN	202	204	TCG	529	531	CCG	212;214;215	C,T;C;G	194,1;197;198	.	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	539	2124	folP	852	852	99.88	folP.l15.c4.ctg.1	1613	131.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1009	1011	AGC	232;232;233	A;G;C	217;215;215	folP.WHO_N_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5386	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3330	161.3	1	SNP	p	S91F	0	.	.	271	273	TCC	569	571	TCC	171;171;173	T;C;C	157;156;160	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5386	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3330	161.3	1	SNP	p	D95G	0	.	.	283	285	GAC	581	583	GAC	178;175;178	G;A;C,T	164;159;162,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5386	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3330	161.3	1	SNP	p	D95N	0	.	.	283	285	GAC	581	583	GAC	178;175;178	G;A;C,T	164;159;162,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1616	mtrR	633	633	97.95	mtrR.l15.c4.ctg.1	1168	137.4	0	.	p	.	0	D79N	NONSYN	235	237	GAT	484	486	AAT	211;206;205	A;A;T	198;192;190	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1616	mtrR	633	633	97.95	mtrR.l15.c4.ctg.1	1168	137.4	0	.	p	.	0	L93P	NONSYN	277	279	CTG	526	528	CCG	203;204;200	C;C;G	186;190;185	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1616	mtrR	633	633	97.95	mtrR.l15.c4.ctg.1	1168	137.4	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	562	564	CAC	203;204;201	C;A;C	183;184;182	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1616	mtrR	633	633	97.95	mtrR.l15.c4.ctg.1	1168	137.4	0	.	p	.	0	N110S	NONSYN	328	330	AAC	577	579	AGC	204;202;205	A;G,A;C	187;184,2;189	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1616	mtrR	633	633	97.95	mtrR.l15.c4.ctg.1	1168	137.4	1	SNP	p	G45D	0	.	.	133	135	GGC	382	384	GGC	193;191;191	G;G;C	182;181;178	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5250	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2915	179.2	1	SNP	p	D86N	0	.	.	256	258	GAC	519	521	GAC	213;212;215	G;A;C	195;191;195	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5250	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2915	179.2	1	SNP	p	S87I	0	.	.	259	261	AGT	522	524	AGT	218;222;223	A;G;T,C	195;197;196,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5250	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2915	179.2	1	SNP	p	S87W	0	.	.	259	261	AGT	522	524	AGT	218;222;223	A;G;T,C	195;197;196,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5250	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2915	179.2	1	SNP	p	S87R	0	.	.	259	261	AGT	522	524	AGT	218;222;223	A;G;T,C	195;197;196,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5250	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2915	179.2	1	SNP	p	S88P	0	.	.	262	264	TCC	525	527	TCC	224;226;226	T;C;C	195;202;203	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4466	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2749	162.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1669	1671	GGC	223;221;218	G;G;C	203;197;197	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4324	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2302	186.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1239	1241	GCA	240;241;243	G;C;A	213;211;219	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4324	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2302	186.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1242	1244	ATC	242;241;241	A;T;C	217;218;218	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4324	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2302	186.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1254	1256	GTG	240;237;238	G;T;G	219;214;213	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4324	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2302	186.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1254	1256	GTG	240;237;238	G;T;G	219;214;213	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4324	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2302	186.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1758	1760	ACC	235;237;235	A;C;C	218;222;220	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4324	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2302	186.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1812	1814	GCG	208;210;208	G;C;G	181;173;179	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4324	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2302	186.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1812	1814	GCG	208;210;208	G;C;G	181;173;179	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4324	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2302	186.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1935	1937	GGC	198;196;195	G;G;C	180;178;177	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4324	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2302	186.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1944	1946	GGC	189;191;191	G;G;C	166;166;167	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4324	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2302	186.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1962	1964	CCG	156;158;158	C,G;C,T;GCCC,GGCCCC	110,2;114,1;110,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5782	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3156	182.8	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1631	1633	CTG	193;193;195	C;T;G	182;184;184	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2242	porA	1146	1146	99.65	porA.l6.c4.ctg.1	1863	119.8	0	.	p	.	0	S22G	NONSYN	64	66	AGC	424	426	GGC	156;155;155	G;G;C,T	146;141;140,1	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2242	porA	1146	1146	99.65	porA.l6.c4.ctg.1	1863	119.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	606	606	C	152	C	140	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3102	porB1b	1035	1035	98.94	porB1b.l15.c17.ctg.1	1340	228.0	0	.	p	.	0	E41K	NONSYN	121	123	GAA	288	290	AAA	258;262;262	A;A;A	239;243;243	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3102	porB1b	1035	1035	98.94	porB1b.l15.c17.ctg.1	1340	228.0	0	.	p	.	0	R143G	NONSYN	427	429	AGA	594	596	GGA	268;267;268	G;G;A	246;247;244	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3102	porB1b	1035	1035	98.94	porB1b.l15.c17.ctg.1	1340	228.0	0	.	p	.	0	Y211del	DEL	631	631	T	798	798	T	255	T	234	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3102	porB1b	1035	1035	98.94	porB1b.l15.c17.ctg.1	1340	228.0	0	.	p	.	0	I214V	NONSYN	640	642	ATC	804	806	GTC	251;250;252	G,A;T;C,G	230,1;225;235,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3102	porB1b	1035	1035	98.94	porB1b.l15.c17.ctg.1	1340	228.0	0	.	p	.	0	L218S	NONSYN	652	654	CTT	816	818	TCT	262;260;258	T;C,T;T	241;242,1;241	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3102	porB1b	1035	1035	98.94	porB1b.l15.c17.ctg.1	1340	228.0	0	.	p	.	0	S254H	NONSYN	760	762	AGT	924	926	CAT	277;282;279	C;A,T;T	259;263,1;260	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3102	porB1b	1035	1035	98.94	porB1b.l15.c17.ctg.1	1340	228.0	1	SNP	p	G120K	0	.	.	358	360	GGT	525	527	GGT	227;226;225	G;G;T,C	214;213;208,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3102	porB1b	1035	1035	98.94	porB1b.l15.c17.ctg.1	1340	228.0	1	SNP	p	A121D	0	.	.	361	363	GCC	528	530	GCC	220;221;226	G,A;C,G;C	204,1;208,1;215	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3102	porB1b	1035	1035	98.94	porB1b.l15.c17.ctg.1	1340	228.0	1	SNP	p	A121N	0	.	.	361	363	GCC	528	530	GCC	220;221;226	G,A;C,G;C	204,1;208,1;215	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11612	rpoB	4179	4179	100.0	rpoB.l6.c17.ctg.1	4920	235.6	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2008	2010	CAT	291;289;291	C;A;T	273;269;273	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1258	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1010	123.9	1	SNP	p	V57M	1	.	.	169	171	ATG	523	525	ATG	276;277;277	A;T;G	250;254;255	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
